IBA receives clearance for new dosimetry product
The FDA has granted 510(k) clearance to Ion Beam Applications (IBA) and RaySearch Laboratories for its new dosimetry solution Compass. The companies will launch the product internationally through IBA's business unit IBA Dosimetry.
The Louvain-la-Neuve, Belgium-based IBA said its Compass is a quality assurance solution in radiotherapy that has been developed in joint cooperation between IBA Dosimetry and RaySearch Laboratories of Stockholm, Sweden. Compass will enable the medical staff to measure and reconstruct the 3D radiation dose delivered to the patient every day during the course of treatment, IBA said.
The company also reported that Compass will increase the safety of radiation therapy as it provides an independent online analysis of both the accuracy of the planned treatment as well as the dose delivered to the patient.
The Louvain-la-Neuve, Belgium-based IBA said its Compass is a quality assurance solution in radiotherapy that has been developed in joint cooperation between IBA Dosimetry and RaySearch Laboratories of Stockholm, Sweden. Compass will enable the medical staff to measure and reconstruct the 3D radiation dose delivered to the patient every day during the course of treatment, IBA said.
The company also reported that Compass will increase the safety of radiation therapy as it provides an independent online analysis of both the accuracy of the planned treatment as well as the dose delivered to the patient.